HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Edward R. Nowicki Eugene H. Blackstone Gurmeet Singh Gonzalo V. Gonzalez-Stawinski Randall C. Starling James B. Young Nicholas G. Smedira Permission Requests Google Scholar Articles by Hoercher, K. J. Articles by Smedira, N. G. PubMed Articles by Hoercher, K. J. Articles by Smedira, N. G. Related Collections Transplantation - heart

J Thorac Cardiovasc Surg 2008;135:1159-1166
© 2008 The American Association for Thoracic Surgery

Cardiothoracic Transplantation

Prognosis of patients removed from a transplant waiting list for medical improvement: Implications for organ allocation and transplantation for status 2 patients

^a Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
^b Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
^c Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
^d Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio

Received for publication November 13, 2007; accepted for publication January 25, 2008.

^_* Address for reprints: Katherine J. Hoercher, RN, Kaufman Center for Heart Failure, Cleveland Clinic, 9500 Euclid Ave/JJ-40, Cleveland, OH 44195. (Email: hoerchk{at}ccf.org).

Objectives: To address the present controversy regarding optimal management of status 2 heart transplant candidates, we studied the short- and long-term fate of medically improved patients removed from our transplant waiting list to assess return of heart failure and occurrence of sudden cardiac death, identify interventions to improve outcomes, and compare their survival with that of similar transplanted patients.

Methods: From January 1985 to February 2004, 100 status 2 patients were delisted for medical improvement (median on-list duration, 314 days). Return of heart failure, sudden cardiac death, and all-cause mortality were determined from follow-up (mean, 7.7 ± 3.9 years among survivors; 10% followed >12 years). Hazard function modeling, competing-risks analyses, simulation, and propensity matching to equivalent patients undergoing transplantation were used to analyze and compare outcomes and predict benefit of interventions.

Results: Freedom from return of heart failure was 77% at 5 years. The most common mode of death was sudden cardiac death, with risk peaking at 2.5 years after delisting but remaining at 3.5% per year thereafter. Event-free survival at 1, 5, and 10 years was 94%, 55%, and 28%, respectively; simulation demonstrated that implantable cardioverter–defibrillators could have improved this to 45% at 10 years. Overall survival after delisting was better than that of matched status 2 patients who underwent transplantation, but was demonstrably worse after 30 months.

Conclusions: Status 2 patients, including those delisted, require vigilant surveillance and optimal medical management, implantable cardioverter–defibrillators, and a revised approach to transplantation timing, such that overall salvage is maximized while allocation of scarce organs is optimized.